Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: a phase 1 …

MLN Disis, KA Guthrie, Y Liu, AL Coveler… - JAMA …, 2023 - jamanetwork.com
Importance High levels of ERBB2 (formerly HER2)–specific type 1 T cells in the peripheral
blood are associated with favorable clinical outcomes after trastuzumab therapy; however …
被引用次数：35 相关文章

Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase …

MLN Disis, KA Guthrie, Y Liu, AL Coveler… - JAMA …, 2023 - europepmc.org
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in
Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized …

Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase …

MLN Disis, KA Guthrie, Y Liu, AL Coveler… - JAMA …, 2023 - pubmed.ncbi.nlm.nih.gov
Importance High levels of ERBB2 (formerly HER2)-specific type 1 T cells in the peripheral
blood are associated with favorable clinical outcomes after trastuzumab therapy; however …
[HTML] nih.gov

[HTML][HTML] Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer …

MLN Disis, KA Guthrie, Y Liu, AL Coveler… - JAMA …, 2023 - ncbi.nlm.nih.gov
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in
Patients With Advanced-Stage ERBB2-Positive Breast Cancer - PMC Back to Top Skip to main …

Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase …

MLN Disis, KA Guthrie, Y Liu, AL Coveler… - JAMA …, 2022 - europepmc.org
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in
Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized …